Page 1

NEXSTIM PLC HALF - YEARLY REPORT 1 JANUARY – 30 JUNE 2021 ( UNAUDITED ) Company announcement , Inside Information , Helsinki , 13 August 2021 at 09:00 am ( EEST ) NEXSTIM'S HISTORICALLY BEST FIRST HALF MEASURED BY NET SALES , OPERATING RESULT AND RESULT FOR THE PERIOD Figures in parentheses refer to the corresponding period of the previous year unless otherwise stated . Summary of January - June 2021 • The company's net sales increased by 83.3 % to EUR 3.0 million ( 1.6 ) Exchange rate - adjusted growth in net sales was 89.5 % and 6.2 percentage points stronger than the reported net sales growth System sales were EUR 1.6 million ( 0.6 ) , an increase of 186.6 % . Recurring revenue accounted for EUR 1.4 million ( 1.1 ) , an increase of 29.3 % . Operating result was EUR -0.9 million ( -1.8 ) with a loss decrease of 50.8 % • The result for the review period was EUR -0.9 million ( -1.2 ) • Net sales of the Diagnostics business ( NBS ) increased by 96.1 % in the first half of the year EUR 1.8 million ( 0.9 ) • Net sales of the Therapy Business ( NBTⓇ ) increased by 67.3 % to EUR 1.2 million ( 0.7 ) in the first half of the year During the spring , a successful rights issue was arranged , which was oversubscribed and a total of EUR 6.6 million in new capital was raised . Funds raised from the rights issue significantly increased the company's equity ratio to 38.9 % ( 4.7 % ) Nexstim • The strategy updated by Nexstim during the review period for 2021-2024 focuses on profitable growth in the Diagnostics and Therapy business Business Overview Nexstim is a Finnish medical technology company operating in the international market , whose neuronavigation TMS technology platform ( transcranial magnetic stimulation , TMS ) enables individual treatment and diagnosis of patients with severe brain diseases and disorders . Nexstim offers solutions for noninvasive brain stimulation in diagnostic ( NBS system ) and therapy applications ( NBTⓇ system ) . Key performance indicators EUR in thousands Net sales Personnel expenses Other operating expenses Depreciation and amortization Operating result Result for the review period Earnings per share ( EUR ) Cash flows from operating activities Cash in hand and at banks Total equity Equity ratio ( % ) Number of shares in the end of the period ( pcs ) Average number of shares during the period ( pcs ) Diluted number of shares in the end of 1-6 / 2021 6 months 2,958.6 -2,028.2 -1,555.0 -172.7 -902.8 -946.3 -0.17 -1.918.7 6,690.8 3,796.7 38.94 6,686,673 5,440,004 7,273,773 1-6 / 2020 6 months 1,614.5 -1,597.3 -1,363.7 - 189.2 -1,836.5 -1,169.1 -1.25 -1,560.6 4,754.2 288.2 4.65 4,396,228 938,740 4,796,368 Change % 83.3 27.0 14.0 -8.7 -50.8 - 19.1 22.9 40.7 1,217.4 34.3 1-12 / 2020 12 months 4,114.0 -3,731.5 -2,429.3 -366.9 -3,332.7 -4,121.6 -1.54 -2,724.7 3,455.8 -1,469.1 -28.25 4,396,228 2,676,931 4,788,348